Lai K N, Leung J W, Loke J, Panesar N S, Swaminathan R, Vallance-Owen J
Int J Artif Organs. 1987 Mar;10(2):109-14.
The clinical efficacy of ultrafiltration (UF) of ascitic fluid with hemofilter in the treatment of intractable ascites associated with chronic liver disease or intraabdominal malignancy was studied in fifteen patients. The ascitic fluid was reinfused into the peritoneal cavity after ultrafiltration. An average of 6.2 liters of fluid was removed during 4.4 hours of ultrafiltration with no significant change in blood pressure, central venous pressure, hemoglobin, platelets or plasma creatinine. Ascitic fluid albumin rose significantly immediately after the procedure (from 5.2 +/- 4.3 gm/L to 31.9 +/- 30.0 gm/L, P less than 0.01). The plasma albumin concentration increased significantly at the end of UF (P less than 0.001). Also there was a significant increase in urine output (P less than 0.001), urinary sodium excretion (P less than 0.001), and endogenous creatinine clearance (P less than 0.01) during the 48 hours following UF. There was no evidence of hemodynamic, renal or hematological dysfunction, and other complications, including encephalopathy, peritonitis and variceal bleeding were not experienced. Ultrafiltration of ascitic fluid with hemofilter may be safely used in the temporary relief of refractory ascites due to cirrhosis or intra-abdominal malignancy.
对15例患者研究了采用血液滤过器超滤腹水治疗慢性肝病或腹腔内恶性肿瘤相关难治性腹水的临床疗效。超滤后的腹水回输至腹腔。超滤4.4小时期间平均清除6.2升液体，血压、中心静脉压、血红蛋白、血小板或血浆肌酐无显著变化。术后腹水白蛋白立即显著升高（从5.2±4.3克/升升至31.9±30.0克/升，P<0.01）。超滤结束时血浆白蛋白浓度显著升高（P<0.001）。超滤后48小时内尿量（P<0.001）、尿钠排泄（P<0.001）和内生肌酐清除率（P<0.01）也显著增加。未发现血流动力学、肾脏或血液学功能障碍的证据，也未出现包括肝性脑病、腹膜炎和曲张静脉出血在内的其他并发症。采用血液滤过器超滤腹水可安全用于暂时缓解肝硬化或腹腔内恶性肿瘤所致难治性腹水。
